1069C85

Drug Profile

1069C85

Alternative Names: 1069C

Latest Information Update: 18 Feb 1997

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Cytostatics
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 18 Feb 1997 Discontinued-II for Cancer in United Kingdom (Unknown route)
  • 08 May 1996 Phase-II clinical trials for Cancer in United Kingdom (Unknown route)
  • 18 Jul 1995 Discontinued-I for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top